Dr. Baram is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
834 Walnut St
Ste 650
Philadelphia, PA 19107Phone+1 215-955-5161Fax+1 215-923-6003- Is this information wrong?
Education & Training
- Brown UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2002 - 2005
- Christiana Care Health ServicesResidency, Internal Medicine/Emergency Medicine, 1997 - 2002
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1997
Certifications & Licensure
- PA State Medical License 2006 - 2024
- MA State Medical License 2003 - 2004
- RI State Medical License 2003 - 2006
- DE State Medical License 1999 - 2009
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Clinical Trials
- Convalescent Plasma for the Treatment of COVID-19 Start of enrollment: 2020 Apr 15
Publications & Presentations
PubMed
- Outcomes of extracorporeal membrane oxygenation in immunosuppressed vs. Immunocompetent patients.Cameron Blazoski, Pradhab Kirupaharan, Robert Hilton, Ron Leong, Michael Baram> ;Heart & lung : the journal of critical care. 2022 Dec 17
- Characteristics of Post-ICU and Post-COVID Recovery Clinics in 29 U.S. Health Systems.Valerie Danesh, Leanne M Boehm, Tammy L Eaton, Alejandro C Arroliga, Kirby P Mayer, Shelli R Kesler, Rita N Bakhru, Michael Baram, Amy L Bellinghausen, Michelle Biehl,...> ;Critical care explorations. 2022 Mar 1
- A multidisciplinary approach to prolonged extracorporeal membrane oxygenation for acute respiratory distress syndrome due to coronavirus 2019-case report.Kathleen Biblowitz, Megan Mullin, Lydia McDermott, Alyssa Sykuta, Michael Baram, Hitoshi Hirose> ;AME case reports. 2022 Jan 1
- Join now to see all
Press Mentions
- Biohaven Receives FDA May Proceed Letter to Begin Phase 2 Trial of Intranasal Vazegepant to Treat Lung Inflammation After COVID-19 InfectionApril 9th, 2020
- COVID-19 Trials Opening at Accelerated RateOctober 20th, 2021
Hospital Affiliations
- Thomas Jefferson University HospitalsPhiladelphia, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: